Adial Pharmaceuticals Inc
ADIL0.239USD
-0.007-2.92%
收盘 12/24, 13:00（美东）报价延迟15分钟
5.71M总市值
亏损市盈率 TTM
关于 Adial Pharmaceuticals Inc 公司
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Adial Pharmaceuticals Inc简介
公司代码ADIL
公司名称Adial Pharmaceuticals Inc
上市日期Jul 27, 2018
CEOClaiborne (Cary J)
员工数量5
证券类型Ordinary Share
年结日Jul 27
公司地址1180 Seminole Trail
城市CHARLOTTESVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编22901
电话14344229800
网址https://www.adialpharma.com/
公司代码ADIL
上市日期Jul 27, 2018
CEOClaiborne (Cary J)
Adial Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Intracoastal Capital, L.L.C.
1.86%
Armistice Capital LLC
1.40%
Geode Capital Management, L.L.C.
0.68%
The Vanguard Group, Inc.
0.65%
Citadel Advisors LLC
0.60%
其他
94.80%
持股股东
持股股东
占比
Intracoastal Capital, L.L.C.
1.86%
Armistice Capital LLC
1.40%
Geode Capital Management, L.L.C.
0.68%
The Vanguard Group, Inc.
0.65%
Citadel Advisors LLC
0.60%
其他
94.80%
股东类型
持股股东
占比
Hedge Fund
2.06%
Corporation
1.88%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
0.68%
Individual Investor
0.36%
Research Firm
0.06%
其他
93.82%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
33
944.43K
1.50%
--
2025Q3
33
944.43K
1.65%
+373.38K
2025Q2
38
571.05K
2.50%
-3.54K
2025Q1
39
574.59K
5.92%
+185.57K
2024Q4
40
638.99K
4.37%
+99.22K
2024Q3
41
539.76K
5.40%
+246.68K
2024Q2
45
293.30K
9.08%
+102.21K
2024Q1
45
191.09K
7.23%
-101.96K
2023Q4
47
264.60K
8.46%
+207.34K
2023Q3
47
57.35K
15.43%
-34.64K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Intracoastal Capital, L.L.C.
446.28K
2.04%
+446.28K
--
Jun 20, 2025
Armistice Capital LLC
336.31K
1.54%
+336.31K
--
Sep 30, 2024
Geode Capital Management, L.L.C.
68.85K
0.32%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
13.16K
0.06%
--
--
Jun 30, 2025
Claiborne (Cary J)
60.80K
0.28%
--
--
Jun 04, 2025
Manchester Capital Management LLC
48.10K
0.22%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
27.77K
0.13%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
12.39K
0.06%
-35.35K
-74.04%
Jun 30, 2025
Newman (James W. Jr.)
13.54K
0.06%
--
--
Jun 04, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
公告日期
类型
比率
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
常见问题
Adial Pharmaceuticals Inc的前五大股东是谁？
Adial Pharmaceuticals Inc 的前五大股东如下：
Intracoastal Capital, L.L.C.持有股份：446.28K，占总股份比例：2.04%。
Armistice Capital LLC持有股份：336.31K，占总股份比例：1.54%。
Geode Capital Management, L.L.C.持有股份：68.85K，占总股份比例：0.32%。
The Vanguard Group, Inc.持有股份：13.16K，占总股份比例：0.06%。
Claiborne (Cary J)持有股份：60.80K，占总股份比例：0.28%。
Intracoastal Capital, L.L.C.持有股份：446.28K，占总股份比例：2.04%。
Armistice Capital LLC持有股份：336.31K，占总股份比例：1.54%。
Geode Capital Management, L.L.C.持有股份：68.85K，占总股份比例：0.32%。
The Vanguard Group, Inc.持有股份：13.16K，占总股份比例：0.06%。
Claiborne (Cary J)持有股份：60.80K，占总股份比例：0.28%。
Adial Pharmaceuticals Inc的前三大股东类型是什么？
Adial Pharmaceuticals Inc 的前三大股东类型分别是：
Intracoastal Capital, L.L.C.
Armistice Capital LLC
Geode Capital Management, L.L.C.
Intracoastal Capital, L.L.C.
Armistice Capital LLC
Geode Capital Management, L.L.C.
有多少机构持有Adial Pharmaceuticals Inc(ADIL)的股份？
截至2025Q4，共有33家机构持有Adial Pharmaceuticals Inc的股份，合计持有的股份价值约为944.43K，占公司总股份的1.50%。与2025Q3相比，机构持股有所增加，增幅为-0.15%。
哪个业务部门对Adial Pharmaceuticals Inc的收入贡献最大？
在--，--业务部门对Adial Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
